Annual General Meeting in ALK-Abelló A/S on 13 March 2025 ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will...
Annual report 2024: ALK delivers 15% sales growth with profits up 65% ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the...
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its...
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system ALK (ALKB:DC / OMX: ALK B / AKBLF) today...
ALK – Financial calendar for the 2025 financial year 2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January...
Positive results advance peanut tablet to phase II development ALK’s peanut tablet shown to be safe and tolerable across multiple...
ACARIZAX® approved in Europe for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for...
ALK’s pivotal phase 3 trial in children published in reputable scientific journal The reputable scientific journal, The Lancet Regional Health –...
Nine-month interim report (Q3) 2024 (unaudited) Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) ALK (ALKB:DC...
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024 ALK (ALKB:DC / OMX: ALK B /...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKBLF): In...
Six-month interim report (Q2) 2024 Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in...
ALK upgrades its full-year revenue and earnings outlook ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook...
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads